Post-approval studies (Phase 4)Study completedNCT02098837
What this trial is testing
Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)
Who this might be right for
HIV
St Stephens Aids Trust 415